Belite Bio (NASDAQ:BLTE) and Alzamend Neuro (NASDAQ:ALZN) Critical Comparison

Belite Bio (NASDAQ:BLTE) and Alzamend Neuro (NASDAQ:ALZN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Volatility and Risk

Belite Bio has a beta of -1.5, indicating that its share price is 250% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500.

Profitability

This table compares Belite Bio and Alzamend Neuro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-34.90%	-33.56%
Alzamend Neuro	N/A	-151.24%	-124.17%

Analyst Recommendations

This is a summary of recent recommendations for Belite Bio and Alzamend Neuro, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	0	0	4	0	3.00
Alzamend Neuro	0	0	1	0	3.00

Belite Bio presently has a consensus price target of $96.00, indicating a potential upside of 43.50%. Alzamend Neuro has a consensus price target of $45.00, indicating a potential upside of 1,617.56%. Given Alzamend Neuro’s higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Belite Bio.

Valuation and Earnings

This table compares Belite Bio and Alzamend Neuro”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$36.14 million	($1.55)	-43.16
Alzamend Neuro	N/A	N/A	-$4.51 million	N/A	N/A

Insider and Institutional Ownership

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 30.2% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Alzamend Neuro beats Belite Bio on 5 of the 8 factors compared between the two stocks.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

About Alzamend Neuro

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.